Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Joseph Franz, Joseph Mikhael, Dhaval Mehta, Rushir Choksi, Taya Salman, Mike Gart, John Li, Harshal Dave, Lisa Kunst, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 3988.

https://doi.org/10.1182/blood-2025-3988

Published: 2025

Journal Articles

Real-world incidence of treatment-emergent cardiovascular events among chronic lymphocytic leukemia/small lymphocytic lymphoma patients receiving acalabrutinib or zanubrutinib monotherapy

Jing-Zhou Hou, Rushir Choksi, Anna Rui, Vikram Shetty, Anna Teschemaker, Kathy Wojtas, Steven Champaloux, Dipen Patel, Doug Kanovsky, Jeffrey Scott, Aliakbar Dadla, Daniel Allendorf

Blood (2025) 146 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2025-4506

Published: 2025

Journal Articles

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Rushir Choksi, Aliakbar Dadla, Thomas Weart, Brian Mulherin, Taral Patel, Fred Kudrik, Tejvir Singh, Anna Rui, Gino Cioffi, Don Parris, Mike Gart, Janet Donegan, Lisa Morere, Lisa Kunst, Lindsay Aton, Poras Dave, Doug Kanovsky, Jeffrey Scott, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2025-4505

Published: 2025

Journal Articles

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Mike Gart, Rhys Williams, Daniel Ermann

Blood (2025) 146 (Supplement 1): 6317.

https://doi.org/10.1182/blood-2025-6317

Published: 2025

Journal Articles

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Blood (2025) 146 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2025-6286

Published: 2025

Journal Articles

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

Rushir Choksi, Aliakbar Dadla, Thomas Weart, Brian Mulherin, Taral Patel, Fred Kudrik, Tejvir Singh, Steven Champaloux, John Li, Anna Rui, Gino Cioffi, Don Parris, Mike Gart, Janet Donegan, Lisa Morere, Lisa Kunst, Lindsay Aton, Jeffrey Scott, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 6285.

https://doi.org/10.1182/blood-2025-6285

Published: 2025

Journal Articles

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Joseph Franz, Dhaval Mehta, Kathleen Dorritie, Rushir Choksi, Taya Salman, Mike Gart, Lisa Kunst, Harshal Dave, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 8120.

https://doi.org/10.1182/blood-2025-8120

Published: 2025

Journal Articles

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Rhys Williams, Daniel Ermann

Blood (2025) 146 (Supplement 1): 8041.

https://doi.org/10.1182/blood-2025-8041

Published: 2025

Journal Articles

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

Jing-Zhou Hou, Tejvir Singh, Wesley Falconer, Patrick Travis, Olalekan Ajayi, Jason Stinnett, Kyle Kitchen, Anna Rui, Mike Gart, Lisa Kunst, Lindsay Aton, Poras Dave, Doug Kanovsky, Brandon Wang, Prateesh Varughese, Robert Geller, Jeffrey Scott, Rushir Choksi

Blood (2025) 146 (Supplement 1): 7934.

https://doi.org/10.1182/blood-2025-7934

Published: 2025

Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Jing-Zhou Hou, Rushir Choksi, Gregory A. Maglinte, Anupama Vasudevan, Anna Rui, Brandon Wang, Hoa Pham, Ann Lasn, Simon Blanc

Blood (2024) 144 (Supplement 1): 2353.

https://doi.org/10.1182/blood-2024-207760

Published: 2024

Journal Articles

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

Jing-Zhou Hou, Rushir Choksi, Anupama Vasudevan, Anna Rui, Poras Davé, Mike Gart, Brandon Wang, Prateesh Varughese, Simon Blanc

Blood (2024) 144 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2024-199765

Published: 2024

Journal Articles

A Patient-Centered Programmatic Approach for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the US Community Oncology Setting

James M. Rossetti, Rushir Choksi, Anupama Vasudevan, Simon Blanc, Dawn Brenneman, Brandon Wang, Peter McMahon, Jason Beal, Teraneh Z. Jhaveri, Mellissa Williamson, Cosmina Hogea

Blood (2023) 142 (Supplement 1): 5101.

https://doi.org/10.1182/blood-2023-186836

Published: 2023

Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

Jing-Zhou Hou, Simon Blanc, Gregory A Maglinte, Anupama Vasudevan, Anna Rui, Michael Gart, Hoa Pham, Lindsay Aton, Brandon Wang, Rushir Choksi

Blood (2023) 142 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2023-174915

Published: 2023

Journal Articles

An Analysis of Ruxolitinib Dosing for Myelofibrosis in Real-World Practice

James M. Rossetti, Rushir Choksi, Purvi Suthar, Phoebe Davis, Anupama Vasudevan, Poras Dave, Varun Vaidya, Brandon Wang, Harvey I. Katzen

Blood (2023) 142 (Supplement 1): 5186.

https://doi.org/10.1182/blood-2023-179402

Published: 2023

Journal Articles

Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL)

Jing-Zhou Hou, Michael Gart, Anupama Vasudevan, Harvey I. Katzen, Rushir Choksi, Simon Blanc

Blood (2023) 142 (Supplement 1): 130.

https://doi.org/10.1182/blood-2023-178685

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Real-world incidence of treatment-emergent cardiovascular events among chronic lymphocytic leukemia/small lymphocytic lymphoma patients receiving acalabrutinib or zanubrutinib monotherapy

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

A Patient-Centered Programmatic Approach for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the US Community Oncology Setting

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

An Analysis of Ruxolitinib Dosing for Myelofibrosis in Real-World Practice

Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only